KemPharm, Inc. (KMPH) EPS Estimated At $-0.69; PHAROL SGPS SA ORD PORTUGAL (PHRZF) Shorts Up By 86.09%

February 18, 2018 - By Maria Brooks

PHAROL SGPS SA ORD PORTUGAL (OTCMKTS:PHRZF) had an increase of 86.09% in short interest. PHRZF’s SI was 274,300 shares in February as released by FINRA. Its up 86.09% from 147,400 shares previously. It closed at $0.29273 lastly. It is down 0.00% since February 18, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts expect KemPharm, Inc. (NASDAQ:KMPH) to report $-0.69 EPS on March, 8.They anticipate $0.01 EPS change or 1.47% from last quarter’s $-0.68 EPS. After having $-0.68 EPS previously, KemPharm, Inc.’s analysts see 1.47% EPS growth. The stock increased 2.62% or $0.1483 during the last trading session, reaching $5.7983. About 117,996 shares traded or 56.80% up from the average. KemPharm, Inc. (NASDAQ:KMPH) has declined 32.16% since February 18, 2017 and is downtrending. It has underperformed by 48.86% the S&P500.

Pharol, SGPS S.A., through its 27.5% interest in Oi, S.A, provides telecommunication services in Portugal, Brazil, Europe, the United Kingdom, Canada, the United States, and Ireland. The company has market cap of $253.40 million. The firm was formerly known as Portugal Telecom, SGPS, SA and changed its name to Pharol, SGPS S.A. in May 2015. It currently has negative earnings.

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. The company has market cap of $84.99 million. The Company’s lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. It currently has negative earnings. The firm is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders.

Among 5 analysts covering KemPharm (NASDAQ:KMPH), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. KemPharm had 15 analyst reports since August 14, 2015 according to SRatingsIntel. Roth Capital maintained the stock with “Buy” rating in Friday, August 11 report. The firm has “Buy” rating by Oppenheimer given on Thursday, August 10. The firm has “Buy” rating given on Wednesday, June 28 by Oppenheimer. RBC Capital Markets maintained KemPharm, Inc. (NASDAQ:KMPH) on Tuesday, January 16 with “Buy” rating. As per Thursday, August 10, the company rating was maintained by Canaccord Genuity. On Friday, August 14 the stock rating was maintained by RBC Capital Markets with “Outperform”. On Thursday, September 17 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Buy” rating by Roth Capital given on Wednesday, June 28. The stock of KemPharm, Inc. (NASDAQ:KMPH) earned “Buy” rating by Canaccord Genuity on Tuesday, December 20. The rating was maintained by Canaccord Genuity on Monday, September 11 with “Buy”.